Literature DB >> 21718559

Atrial fibrillation (acute onset).

Gregory Y H Lip1, Stavros Apostolakis.   

Abstract

INTRODUCTION: Acute atrial fibrillation is rapid, irregular, and chaotic atrial activity of less than 48 hours' duration. Risk factors for acute atrial fibrillation include increasing age, cardiovascular disease, alcohol, diabetes, and lung disease. Acute atrial fibrillation increases the risk of stroke and heart failure. The condition resolves spontaneously within 24 to 48 hours in over 50% of people; however, many people will require interventions to control heart rate or restore sinus rhythm. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent embolism, for conversion to sinus rhythm, and to control heart rate in people with recent-onset atrial fibrillation (within 7 days) who are haemodynamically stable? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 30 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amiodarone, antithrombotic treatment before cardioversion, digoxin, diltiazem, direct current cardioversion, flecainide, propafenone, quinidine, sotalol, timolol, and verapamil.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718559      PMCID: PMC3275309     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  66 in total

Review 1.  Management of atrial fibrillation.

Authors:  Gregory Y H Lip; Antonio Tello-Montoliu
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

2.  Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.

Authors:  C Fresco; A Proclemer; A Pavan; G Buia; A Vicentini; D Pavan; T Morgera
Journal:  Clin Cardiol       Date:  1996-05       Impact factor: 2.882

3.  Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate.

Authors:  Robert Hofmann; Clemens Steinwender; Jürgen Kammler; Alex Kypta; Franz Leisch
Journal:  Int J Cardiol       Date:  2005-07-19       Impact factor: 4.164

4.  Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group.

Authors:  P J Podrid; J L Anderson
Journal:  Am J Cardiol       Date:  1996-08-15       Impact factor: 2.778

5.  Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation.

Authors:  G L Botto; W Bonini; T Broffoni; M Espureo; G Cappelletti; R Lombardi; S Molteni; E Pedraglio; G Ferrari
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

6.  Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study.

Authors:  G E Kochiadakis; N E Igoumenidis; E N Simantirakis; M E Marketou; F I Parthenakis; N E Mezilis; P E Vardas
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

7.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study.

Authors:  M F Stoddard; P R Dawkins; C R Prince; N M Ammash
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

8.  Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).

Authors:  M O Halinen; M Huttunen; S Paakkinen; L Tarssanen
Journal:  Am J Cardiol       Date:  1995-09-01       Impact factor: 2.778

9.  Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study.

Authors:  Z Y Hou; M S Chang; C Y Chen; M S Tu; S L Lin; H T Chiang; R L Woosley
Journal:  Eur Heart J       Date:  1995-04       Impact factor: 29.983

10.  Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation.

Authors:  K D Donovan; B M Power; B E Hockings; G J Dobb; K Y Lee
Journal:  Am J Cardiol       Date:  1995-04-01       Impact factor: 2.778

View more
  1 in total

1.  A case of paroxysmal atrial fibrillation following low voltage electrocution.

Authors:  Mitrakrishnan Rayno Navinan; Thambyaiah Kandeepan; Aruna Kulatunga
Journal:  BMC Res Notes       Date:  2013-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.